Akebia Therapeutics Inc
AKBA1.660USD
-0.040-2.35%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
440.28MMarket Cap
LossP/E TTM
More Details of Akebia Therapeutics Inc Company
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
Akebia Therapeutics Inc Info
Ticker SymbolAKBA
Company nameAkebia Therapeutics Inc
IPO dateMar 20, 2014
CEOButler (John P)
Number of employees181
Security typeOrdinary Share
Fiscal year-endMar 20
Address245 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16178712098
Websitehttps://akebia.com/
Ticker SymbolAKBA
IPO dateMar 20, 2014
CEOButler (John P)
Company Executives of Akebia Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Ms. Leanne M. Zumwalt
Ms. Leanne M. Zumwalt
Independent Director
Independent Director
79.40K
+81.69%
Mr. Nicholas (Nik) Grund
Mr. Nicholas (Nik) Grund
Senior Vice President, Chief Commercial Officer
Senior Vice President, Chief Commercial Officer
45.48K
-89.72%
Mr. Erik Ostrowski
Mr. Erik Ostrowski
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer
--
-100.00%
Dr. Steven K. Burke, M.D.
Dr. Steven K. Burke, M.D.
Senior Vice President - Research and Development, Chief Medical Officer
Senior Vice President - Research and Development, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John P. Butler
Mr. John P. Butler
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.68M
-17.18%
Mr. Adrian Adams
Mr. Adrian Adams
Independent Chairman of the Board
Independent Chairman of the Board
170.50K
+26.48%
Mr. Michael W. Rogers
Mr. Michael W. Rogers
Independent Director
Independent Director
131.73K
+37.18%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
130.93K
+37.49%
Dr. Steven C. Gilman, Ph.D.
Dr. Steven C. Gilman, Ph.D.
Independent Director
Independent Director
122.83K
+40.97%
Dr. Myles Wolf, M.D.
Dr. Myles Wolf, M.D.
Independent Director
Independent Director
103.38K
+52.75%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.30%
The Vanguard Group, Inc.
5.83%
State Street Investment Management (US)
4.46%
Geode Capital Management, L.L.C.
2.33%
Alerce Investment Management, L.P.
2.17%
Other
78.90%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.30%
The Vanguard Group, Inc.
5.83%
State Street Investment Management (US)
4.46%
Geode Capital Management, L.L.C.
2.33%
Alerce Investment Management, L.P.
2.17%
Other
78.90%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.87%
Investment Advisor/Hedge Fund
15.27%
Hedge Fund
7.16%
Research Firm
3.64%
Individual Investor
3.57%
Private Equity
2.18%
Bank and Trust
0.37%
Pension Fund
0.29%
Insurance Company
0.03%
Other
46.61%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
322
132.23M
46.40%
+1.48M
2025Q3
319
130.76M
46.38%
+15.12M
2025Q2
289
114.82M
39.60%
+12.72M
2025Q1
262
102.34M
28.68%
+27.30M
2024Q4
243
68.25M
29.95%
+8.53M
2024Q3
241
59.59M
29.67%
+2.86M
2024Q2
231
56.74M
30.94%
-537.20K
2024Q1
275
57.32M
33.03%
-11.84M
2023Q4
274
54.98M
40.78%
+1.55M
2023Q3
287
53.47M
42.97%
+287.09K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
16.58M
6.25%
+2.61M
+18.71%
Jun 30, 2025
The Vanguard Group, Inc.
14.61M
5.51%
+1.93M
+15.18%
Jun 30, 2025
State Street Investment Management (US)
8.00M
3.02%
+1.19M
+17.50%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.07M
2.29%
+1.04M
+20.75%
Jun 30, 2025
Alerce Investment Management, L.P.
5.75M
2.17%
--
--
Dec 31, 2024
Satter Muneer A
5.75M
2.17%
+5.75M
--
Dec 31, 2024
Renaissance Technologies LLC
4.19M
1.58%
+188.60K
+4.71%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.34M
1.64%
+2.26M
+108.33%
Jun 30, 2025
Qube Research & Technologies Ltd
1.71M
0.65%
+646.27K
+60.50%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
1.9%
Invesco NASDAQ Future Gen 200 ETF
0.38%
State Street SPDR S&P Biotech ETF
0.26%
ALPS Medical Breakthroughs ETF
0.24%
First Trust Small Cap Growth AlphaDEX Fund
0.22%
Federated Hermes MDT Small Cap Core ETF
0.18%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
iShares Micro-Cap ETF
0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.08%
Fidelity Enhanced Small Cap ETF
0.08%
View more
Invesco Biotechnology & Genome ETF
Proportion1.9%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.38%
State Street SPDR S&P Biotech ETF
Proportion0.26%
ALPS Medical Breakthroughs ETF
Proportion0.24%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.22%
Federated Hermes MDT Small Cap Core ETF
Proportion0.18%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.16%
iShares Micro-Cap ETF
Proportion0.11%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.08%
Fidelity Enhanced Small Cap ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Akebia Therapeutics Inc?
The top five shareholders of Akebia Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A. holds 16.58M shares, accounting for 6.25% of the total shares.
The Vanguard Group, Inc. holds 14.61M shares, accounting for 5.51% of the total shares.
State Street Investment Management (US) holds 8.00M shares, accounting for 3.02% of the total shares.
Geode Capital Management, L.L.C. holds 6.07M shares, accounting for 2.29% of the total shares.
Alerce Investment Management, L.P. holds 5.75M shares, accounting for 2.17% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 16.58M shares, accounting for 6.25% of the total shares.
The Vanguard Group, Inc. holds 14.61M shares, accounting for 5.51% of the total shares.
State Street Investment Management (US) holds 8.00M shares, accounting for 3.02% of the total shares.
Geode Capital Management, L.L.C. holds 6.07M shares, accounting for 2.29% of the total shares.
Alerce Investment Management, L.P. holds 5.75M shares, accounting for 2.17% of the total shares.
What are the top three shareholder types of Akebia Therapeutics Inc?
The top three shareholder types of Akebia Therapeutics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of Akebia Therapeutics Inc (AKBA)?
As of 2025Q4, 322 institutions hold shares of Akebia Therapeutics Inc, with a combined market value of approximately 132.23M, accounting for 46.40% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 0.01%.
What is the biggest source of revenue for Akebia Therapeutics Inc?
In --, the -- business generated the highest revenue for Akebia Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
